Oncology Drugs Market by Indication, Drug Class, Route of Administration, Distribution, End-use - Global Forecast 2025-2030- Product Image

Sale

Oncology Drugs Market by Indication, Drug Class, Route of Administration, Distribution, End-use - Global Forecast 2025-2030

Report
197 Pages
October 2024
Region: Global
360iResearch™
ID: 4896719

UP TO €688EUR$697USD£575GBP OFF until Dec 31^st 2024

The Oncology Drugs Market grew from USD 175.78 billion in 2023 to USD 188.41 billion in 2024. It is expected to continue growing at a CAGR of 7.64%, reaching USD 294.42 billion by 2030.

The oncology drugs market encompasses a wide array of therapeutics aimed at combating cancer, including chemotherapy, targeted therapy, immunotherapy, and hormone therapy drugs. With an urgent need to tackle the growing cancer incidence globally, these drugs are essential in extending patient survival time and improving the quality of life. Application spans across various types of malignancies, including lung, breast, colorectal, and prostate cancers, administered in settings ranging from hospitals to specialized cancer treatment centers. Market growth is driven by technological advancements in drug development, increased funding for cancer research, and a robust pipeline of innovative therapies. Furthermore, the rising preference for biologics and biosimilars presents lucrative opportunities for stakeholders, as these drugs promise fewer side effects and improved efficacy. Precision medicine and personalized therapy stand out as burgeoning areas of innovation, offering targeted treatment plans tailored to individual genetic profiles. However, significant challenges such as high costs associated with drug development, stringent regulatory requirements, and side effects of existing treatments pose hurdles. Market dynamics are also influenced by patent expirations leading to increased competition from generics, and variances in regulatory standards across different regions can act as a limiting factor. To capitalize on growth opportunities, stakeholders should focus on collaborations and partnerships, especially in emerging markets where access to affordable treatment remains a challenge. Investment in R&D for novel drug delivery systems and exploring synergistic therapy combinations can uncover new horizons for business growth. It is crucial for market participants to monitor advances in nanotechnology and AI-driven drug discovery, as these could substantially enhance therapeutic impact and streamline drug development processes. Overall, staying abreast of scientific trends and fostering collaborations within the oncology research community can propel comprehensive market insights and strategic advancements.

Understanding Market Dynamics in the Oncology Drugs Market

The Oncology Drugs Market is rapidly evolving, shaped by dynamic supply and demand trends. These insights provide companies with actionable intelligence to drive investments, develop strategies, and seize emerging opportunities. A comprehensive understanding of market dynamics also helps organizations mitigate political, geographical, technical, social, and economic risks while offering a clearer view of consumer behavior and its effects on manufacturing costs and purchasing decisions.

Market Drivers
- Surging prevalence of cancer across the globe
- Increase in investments and government funding in development of cancer drugs
- Growing research & development in personalized medicines
Market Restraints
- High costs associated with the precision medicine therapies
Market Opportunities
- Advancements in genomic sequencing technologies and biotechnology
- Development of biomarker-driven drug development
Market Challenges
- Stringent regulatory requirements and the complexity of drug development

Exploring Porter’s Five Forces for the Oncology Drugs Market

Porter’s Five Forces framework further strengthens the insights of the Oncology Drugs Market, delivering a clear and effective methodology for understanding the competitive landscape. This tool enables companies to evaluate their current competitive standing and explore strategic repositioning by assessing businesses’ power dynamics and market positioning. It is also instrumental in determining the profitability of new ventures, helping companies leverage their strengths, address weaknesses, and avoid potential pitfalls.

Applying PESTLE Analysis to the Oncology Drugs Market

External macro-environmental factors deeply influence the performance of the Oncology Drugs Market, and the PESTLE analysis provides a comprehensive framework for understanding these influences. By examining Political, Economic, Social, Technological, Legal, and Environmental elements, this analysis offers organizations critical insights into potential opportunities and risks. It also helps businesses anticipate changes in regulations, consumer behavior, and economic trends, enabling them to make informed, forward-looking decisions.

Analyzing Market Share in the Oncology Drugs Market

The Oncology Drugs Market share analysis evaluates vendor performance. This analysis provides a clear view of each vendor’s standing in the competitive landscape by comparing key metrics such as revenue, customer base, and other critical factors. Additionally, it highlights market concentration, fragmentation, and trends in consolidation, empowering vendors to make strategic decisions that enhance their market position.

Evaluating Vendor Success with the FPNV Positioning Matrix in the Oncology Drugs Market

The Oncology Drugs Market FPNV Positioning Matrix is crucial in evaluating vendors based on business strategy and product satisfaction levels. By segmenting vendors into four quadrants - Forefront (F), Pathfinder (P), Niche (N), and Vital (V) - this matrix helps users make well-informed decisions that best align with their unique needs and objectives in the market.

Strategic Recommendations for Success in the Oncology Drugs Market

The Oncology Drugs Market strategic analysis is essential for organizations aiming to strengthen their position in the global market. A comprehensive review of resources, capabilities, and performance helps businesses identify opportunities for improvement and growth. This approach empowers companies to navigate challenges in the increasingly competitive landscape, ensuring they capitalize on new opportunities and align with long-term success.

Key Company Profiles

The report delves into recent significant developments in the Oncology Drugs Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Agenus Inc., Amgen Inc., Aspen Pharmacare Holdings Limited, Astellas Pharma Inc., AstraZeneca PLC, Bayer AG, BeiGene, Inc., Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Cipla Limited, Debiopharm International SA, Eli Lilly and Company, EMD Serono, Inc. by Merck KGaA, F. Hoffmann-La Roche Ltd., GlaxoSmithKline PLC, Johnson & Johnson Services, Inc., Pfizer Inc., Puma Biotechnology, Inc., Shorla Pharma Ltd., Sun Pharmaceutical Industries Ltd., Sutro Biopharma, Inc., Takeda Pharmaceutical Company Limited, and Viatris Inc..

Market Segmentation & Coverage

This research report categorizes the Oncology Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

Indication
- Bladder Cancer
- Breast Cancer
- Cervical Cancer
- Colorectal Cancer
- Esophagus Cancer
- Kidney Cancer
- Liver Cancer
- Lung Cancer
- Prostate Cancer
- Stomach Cancer
Drug Class
- Chemotherapy
- Hormonal Therapy
- Immunotherapy
- Targeted Therapy
Route of Administration
- Intravenous
- Oral
- Topical
Distribution
- Offline Pharmacies
  - Hospital Pharmacies
  - Retail Pharmacies
- Online Pharmacies
End-use
- Home Healthcare
- Hospitals
- Specialty Cancer Clinics

Region
- Americas
  - Argentina
  - Brazil
  - Canada
  - Mexico
  - United States
    - California
    - Florida
    - Illinois
    - New York
    - Ohio
    - Pennsylvania
    - Texas
- Asia-Pacific
  - Australia
  - China
  - India
  - Indonesia
  - Japan
  - Malaysia
  - Philippines
  - Singapore
  - South Korea
  - Taiwan
  - Thailand
  - Vietnam
- Europe, Middle East & Africa
  - Denmark
  - Egypt
  - Finland
  - France
  - Germany
  - Israel
  - Italy
  - Netherlands
  - Nigeria
  - Norway
  - Poland
  - Qatar
  - Russia
  - Saudi Arabia
  - South Africa
  - Spain
  - Sweden
  - Switzerland
  - Turkey
  - United Arab Emirates
  - United Kingdom

The report provides a detailed overview of the market, exploring several key areas:

Market Penetration: A thorough examination of the current market landscape, featuring comprehensive data from leading industry players and analyzing their reach and influence across the market.
Market Development: The report identifies significant growth opportunities in emerging markets and assesses expansion potential within established segments, providing a roadmap for future development.
Market Diversification: In-depth coverage of recent product launches, untapped geographic regions, significant industry developments, and strategic investments reshaping the market landscape.
Competitive Assessment & Intelligence: A detailed analysis of the competitive landscape, covering market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, technological advancements, and innovations in manufacturing by key market players.
Product Development & Innovation: Insight into groundbreaking technologies, R&D efforts, and product innovations that will drive the market in future.

Additionally, the report addresses key questions to assist stakeholders in making informed decisions:

What is the current size of the market, and how is it expected to grow?
Which products, segments, and regions present the most attractive investment opportunities?
What are the prevailing technology trends and regulatory factors influencing the market?
How do top vendors rank regarding market share and competitive positioning?
What revenue sources and strategic opportunities guide vendors' market entry or exit decisions?

Please note: For this report, the purchase of an Enterprise license allows up to ten worldwide users of an organization access to the report

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary
4. Market Overview

5. Market Insights

5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Surging prevalence of cancer across the globe
5.1.1.2. Increase in investments and government funding in development of cancer drugs
5.1.1.3. Growing research & development in personalized medicines
5.1.2. Restraints
5.1.2.1. High costs associated with the precision medicine therapies
5.1.3. Opportunities
5.1.3.1. Advancements in genomic sequencing technologies and biotechnology
5.1.3.2. Development of biomarker-driven drug development
5.1.4. Challenges
5.1.4.1. Stringent regulatory requirements and the complexity of drug development
5.2. Market Segmentation Analysis
5.2.1. Drug Class: Growing significance of targeted therapy due to its precision and lower side effects
5.2.2. End-use: Ongoing expansion of specialty cancer clinics accelerating the demand for oncology drugs
5.3. Porter’s Five Forces Analysis
5.3.1. Threat of New Entrants
5.3.2. Threat of Substitutes
5.3.3. Bargaining Power of Customers
5.3.4. Bargaining Power of Suppliers
5.3.5. Industry Rivalry
5.4. PESTLE Analysis
5.4.1. Political
5.4.2. Economic
5.4.3. Social
5.4.4. Technological
5.4.5. Legal
5.4.6. Environmental

6. Oncology Drugs Market, by Indication

6.1. Introduction
6.2. Bladder Cancer
6.3. Breast Cancer
6.4. Cervical Cancer
6.5. Colorectal Cancer
6.6. Esophagus Cancer
6.7. Kidney Cancer
6.8. Liver Cancer
6.9. Lung Cancer
6.10. Prostate Cancer
6.11. Stomach Cancer

7. Oncology Drugs Market, by Drug Class

7.1. Introduction
7.2. Chemotherapy
7.3. Hormonal Therapy
7.4. Immunotherapy
7.5. Targeted Therapy

8. Oncology Drugs Market, by Route of Administration

8.1. Introduction
8.2. Intravenous
8.3. Oral
8.4. Topical

9. Oncology Drugs Market, by Distribution

9.1. Introduction
9.2. Offline Pharmacies
9.2.1. Hospital Pharmacies
9.2.2. Retail Pharmacies
9.3. Online Pharmacies

10. Oncology Drugs Market, by End-use

10.1. Introduction
10.2. Home Healthcare
10.3. Hospitals
10.4. Specialty Cancer Clinics

11. Americas Oncology Drugs Market

11.1. Introduction
11.2. Argentina
11.3. Brazil
11.4. Canada
11.5. Mexico
11.6. United States

12. Asia-Pacific Oncology Drugs Market

12.1. Introduction
12.2. Australia
12.3. China
12.4. India
12.5. Indonesia
12.6. Japan
12.7. Malaysia
12.8. Philippines
12.9. Singapore
12.10. South Korea
12.11. Taiwan
12.12. Thailand
12.13. Vietnam

13. Europe, Middle East & Africa Oncology Drugs Market

13.1. Introduction
13.2. Denmark
13.3. Egypt
13.4. Finland
13.5. France
13.6. Germany
13.7. Israel
13.8. Italy
13.9. Netherlands
13.10. Nigeria
13.11. Norway
13.12. Poland
13.13. Qatar
13.14. Russia
13.15. Saudi Arabia
13.16. South Africa
13.17. Spain
13.18. Sweden
13.19. Switzerland
13.20. Turkey
13.21. United Arab Emirates
13.22. United Kingdom

14. Competitive Landscape

14.1. Market Share Analysis, 2023
14.2. FPNV Positioning Matrix, 2023
14.3. Competitive Scenario Analysis
14.3.1. FDA Approves XTANDI for High-Risk Prostate Cancer Management
14.3.2. Takeda's FRUZAQLA Receives FDA Approval for Metastatic Colorectal Cance
14.3.3. FDA Approves Takeda's FRUZAQLA, a Novel Treatment for Metastatic Colorectal Cancer
14.4. Strategy Analysis & Recommendation

List of Figures

FIGURE 1. ONCOLOGY DRUGS MARKET RESEARCH PROCESS
FIGURE 2. ONCOLOGY DRUGS MARKET SIZE, 2023 VS 2030
FIGURE 3. GLOBAL ONCOLOGY DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
FIGURE 7. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 8. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
FIGURE 9. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 10. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
FIGURE 11. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 12. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2023 VS 2030 (%)
FIGURE 13. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 14. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2023 VS 2030 (%)
FIGURE 15. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 16. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 17. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 18. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 19. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 20. ASIA-PACIFIC ONCOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 21. ASIA-PACIFIC ONCOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 23. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 24. ONCOLOGY DRUGS MARKET SHARE, BY KEY PLAYER, 2023
FIGURE 25. ONCOLOGY DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

List of Tables

TABLE 1. ONCOLOGY DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. GLOBAL ONCOLOGY DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. ONCOLOGY DRUGS MARKET DYNAMICS
TABLE 7. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY BLADDER CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY CERVICAL CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY ESOPHAGUS CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY KIDNEY CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY LIVER CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY STOMACH CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY HORMONAL THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY SPECIALTY CANCER CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 38. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 39. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 40. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 41. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 42. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 43. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 44. ARGENTINA ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 45. ARGENTINA ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 46. ARGENTINA ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 47. ARGENTINA ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 48. ARGENTINA ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 49. ARGENTINA ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 50. BRAZIL ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 51. BRAZIL ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 52. BRAZIL ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 53. BRAZIL ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 54. BRAZIL ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 55. BRAZIL ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 56. CANADA ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 57. CANADA ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 58. CANADA ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 59. CANADA ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 60. CANADA ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 61. CANADA ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 62. MEXICO ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 63. MEXICO ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 64. MEXICO ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 65. MEXICO ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 66. MEXICO ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 67. MEXICO ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 68. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 69. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 70. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 71. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 72. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 73. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 74. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 75. ASIA-PACIFIC ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 76. ASIA-PACIFIC ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 77. ASIA-PACIFIC ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 78. ASIA-PACIFIC ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 79. ASIA-PACIFIC ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 80. ASIA-PACIFIC ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 81. ASIA-PACIFIC ONCOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 82. AUSTRALIA ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 83. AUSTRALIA ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 84. AUSTRALIA ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 85. AUSTRALIA ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 86. AUSTRALIA ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 87. AUSTRALIA ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 88. CHINA ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 89. CHINA ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 90. CHINA ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 91. CHINA ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 92. CHINA ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 93. CHINA ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 94. INDIA ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 95. INDIA ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 96. INDIA ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 97. INDIA ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 98. INDIA ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 99. INDIA ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 100. INDONESIA ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 101. INDONESIA ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 102. INDONESIA ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 103. INDONESIA ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 104. INDONESIA ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 105. INDONESIA ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 106. JAPAN ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 107. JAPAN ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 108. JAPAN ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 109. JAPAN ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 110. JAPAN ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 111. JAPAN ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 112. MALAYSIA ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 113. MALAYSIA ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 114. MALAYSIA ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 115. MALAYSIA ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 116. MALAYSIA ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 117. MALAYSIA ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 118. PHILIPPINES ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 119. PHILIPPINES ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 120. PHILIPPINES ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 121. PHILIPPINES ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 122. PHILIPPINES ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 123. PHILIPPINES ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 124. SINGAPORE ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 125. SINGAPORE ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 126. SINGAPORE ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 127. SINGAPORE ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 128. SINGAPORE ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 129. SINGAPORE ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 130. SOUTH KOREA ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 131. SOUTH KOREA ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 132. SOUTH KOREA ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 133. SOUTH KOREA ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 134. SOUTH KOREA ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 135. SOUTH KOREA ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 136. TAIWAN ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 137. TAIWAN ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 138. TAIWAN ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 139. TAIWAN ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 140. TAIWAN ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 141. TAIWAN ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 142. THAILAND ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 143. THAILAND ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 144. THAILAND ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 145. THAILAND ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 146. THAILAND ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 147. THAILAND ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 148. VIETNAM ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 149. VIETNAM ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 150. VIETNAM ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 151. VIETNAM ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 152. VIETNAM ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 153. VIETNAM ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 154. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 155. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 156. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 157. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 158. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 159. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 160. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 161. DENMARK ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 162. DENMARK ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 163. DENMARK ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 164. DENMARK ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 165. DENMARK ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 166. DENMARK ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 167. EGYPT ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 168. EGYPT ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 169. EGYPT ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 170. EGYPT ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 171. EGYPT ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 172. EGYPT ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 173. FINLAND ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 174. FINLAND ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 175. FINLAND ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 176. FINLAND ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 177. FINLAND ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 178. FINLAND ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 179. FRANCE ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 180. FRANCE ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 181. FRANCE ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 182. FRANCE ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 183. FRANCE ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 184. FRANCE ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 185. GERMANY ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 186. GERMANY ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 187. GERMANY ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 188. GERMANY ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 189. GERMANY ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 190. GERMANY ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 191. ISRAEL ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 192. ISRAEL ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 193. ISRAEL ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 194. ISRAEL ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 195. ISRAEL ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 196. ISRAEL ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 197. ITALY ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 198. ITALY ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 199. ITALY ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 200. ITALY ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 201. ITALY ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 202. ITALY ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 203. NETHERLANDS ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 204. NETHERLANDS ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 205. NETHERLANDS ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 206. NETHERLANDS ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 207. NETHERLANDS ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 208. NETHERLANDS ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 209. NIGERIA ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 210. NIGERIA ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 211. NIGERIA ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 212. NIGERIA ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 213. NIGERIA ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 214. NIGERIA ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 215. NORWAY ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 216. NORWAY ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 217. NORWAY ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 218. NORWAY ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 219. NORWAY ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 220. NORWAY ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 221. POLAND ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 222. POLAND ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 223. POLAND ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 224. POLAND ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 225. POLAND ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 226. POLAND ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 227. QATAR ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 228. QATAR ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 229. QATAR ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 230. QATAR ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 231. QATAR ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 232. QATAR ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 233. RUSSIA ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 234. RUSSIA ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 235. RUSSIA ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 236. RUSSIA ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 237. RUSSIA ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 238. RUSSIA ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 239. SAUDI ARABIA ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 240. SAUDI ARABIA ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 241. SAUDI ARABIA ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 242. SAUDI ARABIA ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 243. SAUDI ARABIA ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 244. SAUDI ARABIA ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 245. SOUTH AFRICA ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 246. SOUTH AFRICA ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 247. SOUTH AFRICA ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 248. SOUTH AFRICA ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 249. SOUTH AFRICA ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 250. SOUTH AFRICA ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 251. SPAIN ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 252. SPAIN ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 253. SPAIN ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 254. SPAIN ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 255. SPAIN ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 256. SPAIN ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 257. SWEDEN ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 258. SWEDEN ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 259. SWEDEN ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 260. SWEDEN ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 261. SWEDEN ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 262. SWEDEN ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 263. SWITZERLAND ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 264. SWITZERLAND ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 265. SWITZERLAND ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 266. SWITZERLAND ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 267. SWITZERLAND ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 268. SWITZERLAND ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 269. TURKEY ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 270. TURKEY ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 271. TURKEY ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 272. TURKEY ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 273. TURKEY ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 274. TURKEY ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 275. UNITED ARAB EMIRATES ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 276. UNITED ARAB EMIRATES ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 277. UNITED ARAB EMIRATES ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 278. UNITED ARAB EMIRATES ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 279. UNITED ARAB EMIRATES ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 280. UNITED ARAB EMIRATES ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 281. UNITED KINGDOM ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 282. UNITED KINGDOM ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 283. UNITED KINGDOM ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 284. UNITED KINGDOM ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 285. UNITED KINGDOM ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 286. UNITED KINGDOM ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 287. ONCOLOGY DRUGS MARKET SHARE, BY KEY PLAYER, 2023
TABLE 288. ONCOLOGY DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

Companies Mentioned

The leading players in the Oncology Drugs market, which are profiled in this report, include:

AbbVie Inc.
Agenus Inc.
Amgen Inc.
Aspen Pharmacare Holdings Limited
Astellas Pharma Inc.
AstraZeneca PLC
Bayer AG
BeiGene, Inc.
Boehringer Ingelheim GmbH
Bristol-Myers Squibb Company
Cipla Limited
Debiopharm International SA
Eli Lilly and Company
EMD Serono, Inc. by Merck KGaA
F. Hoffmann-La Roche Ltd.
GlaxoSmithKline PLC
Johnson & Johnson Services, Inc.
Pfizer Inc.
Puma Biotechnology, Inc.
Shorla Pharma Ltd.
Sun Pharmaceutical Industries Ltd.
Sutro Biopharma, Inc.
Takeda Pharmaceutical Company Limited
Viatris Inc.

Methodology

LOADING...

Table Information

Report Attribute	Details
No. of Pages	197
Published	October 2024
Forecast Period	2024 - 2030
Estimated Market Value ( USD ) in 2024	$ 188.41 Billion
Forecasted Market Value ( USD ) by 2030	$ 294.42 Billion
Compound Annual Growth Rate	7.6%
Regions Covered	Global
No. of Companies Mentioned	25

License	Format	Properties	Price
SINGLE USER LICENSE PDF, Excel and Online Access		This is a single user license, allowing one user access to the product.	€3501EUR$3,545USD£2,923GBP €3890EUR$3,939USD£3,248GBP
ENTERPRISE LICENSE PDF, Excel and Online Access		This is an enterprise license, allowing all employees within your organization access to the product.	€6193EUR$6,272USD£5,172GBP €6881EUR$6,969USD£5,746GBP

Understanding Market Dynamics in the Oncology Drugs Market

Exploring Porter’s Five Forces for the Oncology Drugs Market

Applying PESTLE Analysis to the Oncology Drugs Market

Analyzing Market Share in the Oncology Drugs Market

Evaluating Vendor Success with the FPNV Positioning Matrix in the Oncology Drugs Market

Strategic Recommendations for Success in the Oncology Drugs Market

Key Company Profiles

Market Segmentation & Coverage

The report provides a detailed overview of the market, exploring several key areas:

Additionally, the report addresses key questions to assist stakeholders in making informed decisions:

Table of Contents

Companies Mentioned

Methodology

Table Information

Related Topics

Related Reports

United States Cancer Drugs Market: Prospects, Trends Analysis, Market Size and Forecasts up to 2032

North America Oncology Drugs Market Size, Share & Industry Trends Analysis Report By Indication, By Drug Class Type (Targeted Therapy, Immunotherapy (Biologic Therapy), Chemotherapy and Hormonal Therapy), By Country and Growth Forecast, 2023 - 2030

Cancer Drugs Market by Route of Administration, Type of Therapy, Type, End-User - Global Forecast 2025-2030

Generic Oncology Drugs Market by Drug Class, Therapy Type, Cancer Type, Route Of Administration, End User - Global Forecast 2025-2030

Anti-Tumor Drugs Market by Indications, Route of Administration, Drug Class, Distribution Channels, End User - Global Forecast 2025-2030

About the Oncology Drugs Market